Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Kelly, Godby"'
Autor:
Nadia M. Anabtawi, Monica Sai Pasala, Alyssa A. Grimshaw, Prakash Kharel, Susan Bal, Kelly Godby, Ashmita Siwakoti, Thomas W. Buford, Smita Bhatia, Luciano J. Costa, Grant R. Williams, Smith Giri
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 3, Pp 1084-1093 (2024)
Abstract Background Low skeletal muscle mass (LSMM) and/or, function associated with an increased risk of treatment‐related toxicities and inferior overall survival (OS) among adults with solid malignancies. However, the association between LSMM an
Externí odkaz:
https://doaj.org/article/af902c648c5746f4abe5b7abfad8f3d2
Autor:
Luciano Costa, Eva Medvedova, Sarabh Chhabra, Bhagirathbhai Dholaria, Binod Dhakal, Kelly Godby, Rebecca Silberman, Susan Bal, Anita D’souza, Smith Giri, Timothy Schmidt, James Omel, Parameswaran Hari, Natalie Callander
Publikováno v:
HemaSphere, Vol 7, p e1332195 (2023)
Externí odkaz:
https://doaj.org/article/853ccff73cbf4befaefddb7ce54cbcc2
Autor:
Carl Zainaldin, Sankalp Arora, Srilakshmi Bathini, Udita Gupta, Vishruti Pandya, Sejong Bae, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D. Oliver, Donna Salzman, Antonio Di Stasi, Pankit Vachhani
Publikováno v:
Leukemia & Lymphoma. 63:3245-3248
Autor:
Luciano J. Costa, Ilene K. Brill, James Omel, Kelly Godby, Shaji K. Kumar, Elizabeth E. Brown
Publikováno v:
Blood Advances, Vol 1, Iss 4, Pp 282-287 (2017)
Abstract: Prior improvements in multiple myeloma (MM) survival were not fully observed in racial and ethnic minorities and older individuals. We hypothesized that improvements in MM management in recent years have reduced these disparities. We used t
Externí odkaz:
https://doaj.org/article/509ccb4af0a04d348fac7e1f135ceb3b
Autor:
Sankalp Arora, Carl Zainaldin, Srilakshmi Bathini, Udita Gupta, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D. Oliver, Donna Salzman, Antonio Di Stasi, Pankit Vachhani
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:CLO22-037
Autor:
Natalie S. Callander, Muhamed Baljevic, Kehinde Adekola, Larry D. Anderson, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Srinivas Devarakonda, Noura Elsedawy, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Michaela Liedtke, Thomas Martin, James Omel, Douglas Sborov, Kenneth Shain, Keith Stockerl-Goldstein, Donna Weber, Ryan A. Berardi, Rashmi Kumar, Shaji K. Kumar
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:8-19
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights high
Autor:
Sonia Gowda, Rebecca Silbermann, Timothy Schmidt, Binod Dhakal, Susan Bal, Eden Biltibo, Saurabh Chhabra, Bhagirathbhai Dholaria, Smith Giri, Kelly Godby, Eva Medvedova, Natalie Callander, Luciano Costa
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S15-S16
Autor:
Priscila White, Abigail Cooley, Susan Bal, Kelly Godby, Gayathri Ravi, Deanna Clark, Clare Ubersax, Grant R. Williams, Luciano J. Costa, Smith Giri
Publikováno v:
Journal of geriatric oncology. 13(8)
Autor:
Smith Giri, Susan Bal, Kelly Godby, Gayathri Ravi, Deanna Clark, Clare Ubersax, Abigail Cooley, Priscila White, Grant Williams, Luciano J. Costa
Publikováno v:
Transplantation and Cellular Therapy. 28:S441-S442
Autor:
Sankalp Arora, Carl Zainaldin, Srilakshmi Bathini, Udita Gupta, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D. Oliver, Donna Salzman, Antonio Di Stasi, Pankit Vachhani
Publikováno v:
Leukemia Research. 117:106844
Venetoclax (Ven) in combination with azacitidine or decitabine (hypomethylating agent; HMA) is the standard-of-care treatment for older (≥75 years) or intensive chemotherapy ineligible adults with newly diagnosed acute myeloid leukemia (AML). Tumor